TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04301271
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 weeks Placebo add-on
Study: NCT00967811
Drug: Formulation E1 of L-PPDS
Normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control of IOP compared to baseline for Formulation E1 of the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
Study: NCT00967811
Drug: Formulation E2 of L-PPDS
Normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control of IOP compared to baseline for Formulation E2 of experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
Study: NCT03818256
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets for once-daily oral dosing
Study: NCT00280540
Drug: Valsartan/Hydrochlorothiazide
Normalized name: valsartan/hydrochlorothiazide 160 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02616120
Drug: SQJZ herbal mixtures
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: The SQJZ herbal mixtures is Chinese herb extracts. It contains Rehmannia glutinosa Libosch，Astragalus membranaceus (Fisch.) Bunge etc.( 29.375g, 2 times per day)
Study: NCT02616120
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo contains 5%SQJZ herbal mixtures and 95% dextrin,identified to SQJZ herbal formula (29.375g, 2 times per day)
Study: NCT01884675
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: White, film-coated, ambrisentan-matching placebo tablet for single oral dose
Study: NCT01285557
Drug: Fluorouracil/cisplatin (control arm)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU: 800 mg/m2 BSA/24 hours by continuous intravenous infusion (CIV) from Days 1 through 5 plus cisplatin 80 mg/m2 BSA on Day 1 each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops. Treatment with cisplatin is limited to a maximum of 8 cycles.
Study: NCT00033683
Drug: CMF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00033683
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00033683
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00033683
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02061020
Drug: Cannabis (THC) in cigarettes of 30mg, 10mg and placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoked THC containing cigarettes. Randomly allocated dosage 30mg, 10mg et placebo.~Both chronic and occasional cannabis consuming volunteers will be allocated to smoking a cigarette containing (1) no THC (placebo), (2) a joint containing 1% THC (10 mg THC, i.e. low-dose) and (3) a joint containing 3% (30 mg THC) mixed with 1 g tobacco.~Each cigarette will be followed by 24 hours testing in laboratory conditions. Each period is separated by 7 days (3 testing periods over 3 weeks). Each volunteer will undergo performance testing (driving simulator and PVT) before administration of the substance (T0).~Blood samples and repeat performance testing will be carried out at 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours.
Study: NCT03914131
Drug: Xinnaoning Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinnaoning Capsule used in study group(treatment period) is the true drug that the investigators are to evaluate.
Study: NCT01491802
Drug: LAMA/LABA
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK573719/GW642444 inhalation powder used in the Novel Dry Powder Inhaler (DPI): a long-acting beta2-agonist (GSK642444, 25mcg) with a long-acting muscarinic antagonist (GSK573719, 125mcg) combination therapy will be taken once daily for 4 weeks.
Study: NCT01005966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo and washout treatment
Study: NCT01005966
Drug: 675 ppmf toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose response
Study: NCT00231959
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill
Study: NCT03741075
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical application of 200ml saline to the placental bed after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
Study: NCT00001256
Drug: prednisone and methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04087733
Drug: OZODROP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 days before the cataract surgery (T0), two conjunctival swabs will be taken from the patients enrolled in the study, one in the eye to be operated and one in the control eye, who will be kept at a controlled temperature (+ 2 / + 7 ° C) and sent to the laboratory within 24 hours. Than, starting on the day of collection, the patients will instill the OZODROP® eye drops in the eye to be used (2 drops 4 times a day, 1 drop every 4 hours: 9:00 am, 1:00 pm, 5:00 pm: 00, h21: 00), while the contralateral eye will be treated with a saline solution and it will serve as a control. Immediately before the cataract surgery (T3), the patients enrolled in the study will again receive two conjunctival swabs, one in the eye to be operated and one in the control eye. The last OZODROP® instillation will be carried out 10 minutes before the withdrawal. For the microbiological evaluation, the conjunctival swabs taken at T0 and T3 will be sent to the Microbiology laboratory
Study: NCT00039377
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT and IV
Study: NCT02420717
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00039377
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV and PO
Study: NCT00039377
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02420717
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02420717
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT02420717
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02420717
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV and PO
Study: NCT02419495
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02419495
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02419495
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02419495
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02419495
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02471898
Drug: HTX-011
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02471898
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT02079077
Drug: Acetylsalicylic Acid (ASA)
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic Acid (ASA) 81 mg. oral daily for two months
Study: NCT03758612
Drug: Placebo suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for TBI-223 oral Suspension; orally administered.
Study: NCT02373176
Drug: [14C]PRC 4016 (Icosabutate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT03003325
Drug: AOP2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: AOP2014 will be supplied to the patients as pre-filled auto-injection pens, containing 250 µg of active drug (0.5 ml solution for injection). One pen may be used twice within a time period of 4 weeks. Hence investigators will provide one prefilled pen at every monthly visit. AOP2014 will be self-injected subcutaneously by patients once every 14 days at the single doses of 100 µg (0.2 ml).
Study: NCT01648751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gram vaginally for 7 days, followed by 1 gram vaginally twice weekly thereafter
Study: NCT02991768
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is matched to the study drug.
Study: NCT02257970
Drug: Ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02257970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match ketoprofen.
Study: NCT04158362
Drug: Capecitabine tablets
Normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is given orally at a dose of 2000 to 2500 mg/m² daily for 14 days followed by a 7-day rest period every 3 weeks
Study: NCT00490828
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone
Study: NCT02136927
Drug: SPARC1210
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02201953
Drug: SOF/VEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100 mg FDC tablet administered orally once daily
Study: NCT02201953
Drug: SOF
Normalized name: Kasof
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg tablet administered orally once daily
Study: NCT00883896
Drug: ILV-094
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: ILV-094 100 mg SC every 4 weeks (alternating ILV-094 100 mg and placebo every 2 weeks) X 10 weeks.
Study: NCT00883896
Drug: ILV-094
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: ILV-094 100 mg SC every 2 weeks X 10 weeks.
Study: NCT00883896
Drug: ILV-094
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 2: ILV-094 200 mg SC every 2 weeks X 10 weeks
Study: NCT04632316
Drug: Cyclophosphamide-Fludarabine (Cy/Flu)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphodepleting conditioning regimen
Study: NCT04632316
Drug: oNKord®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
Study: NCT00504816
Drug: GSK189075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given with Brevicon to determine any effects of GSK189075 on Brevicon PK.
Study: NCT00005803
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04138758
Drug: LABA/ICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
Study: NCT03294707
Drug: AG10 oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active single ascending dose
Study: NCT03294707
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo single dose
Study: NCT03904849
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral solution
Study: NCT02096601
Drug: LD/CD SC solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/carbidopa SC solution
Study: NCT04679064
Drug: Pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy drug
Study: NCT03088306
Drug: Standard analgesia use [Volatile Anesthesia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
Study: NCT03088306
Drug: Standard analgesia use [Fentanyl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
Study: NCT03088306
Drug: Multi-modal pain management [Acetaminophen + Gabapentin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
Study: NCT03088306
Drug: Multi-modal pain management [Fentanyl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
Study: NCT01695226
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pre-operative celecoxib (400 mg) twice daily for two to three weeks
Study: NCT01695226
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: pre-operative placebo twice daily for two to three weeks
Study: NCT04035824
Drug: Gastrodia and Uncaria granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients allocated to the intervention group take 10g of Gastrodia and Uncaria granule each time, twice per day, and for two months.
Study: NCT04035824
Drug: Placebo of Gastrodia and Uncaria granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients allocated to the control group take 10g of placebo of Gastrodia and Uncaria granule each time, twice per day, and for two months. The placebo has similar appearance and smell to genuine drug but has no effective anti-hypertensive agents.
Study: NCT03431688
Drug: PBMT
Normalized name: Photobiomodulation Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment with PPI, metonidazole, bismuth, tetracyclin
Study: NCT04311515
Drug: PU-AD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PU-AD 30mg daily for 6mos
Study: NCT01887327
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered by IM injection
Study: NCT04311515
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 30mg daily for 6mos
Study: NCT02172274
Drug: [14C]-BI 10773 - oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02220920
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will receive Placebo orally for 16 weeks
Study: NCT03198715
Drug: DS1040b
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-1040b in solution for intravenous infusion
Study: NCT03198715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution for intravenous infusion
Study: NCT02040415
Drug: Myonal Tab.(eperisone HCl) 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02040415
Drug: Placebo drug of Myonal Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02135432
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00253747
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS-MPH (placebo) dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
Study: NCT01917396
Drug: Fleet enema
Normalized name: Fleet Enema
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02433418
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Women will receive oral diclofenac 50 mg (voltaren ®) 1 hour before hysterosalpingography
Study: NCT04501523
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600-750 mg/m2 PO Bid，continuous, for 1 year
Study: NCT03776968
Drug: HC1119
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01733758
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albiglutide matching placebo will be available as a pen injector
Study: NCT01399619
Drug: PegIFN/RBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFN/RBV for 24 or 48w
Study: NCT01399619
Drug: BI201335
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI201335 for 12w
Study: NCT01399619
Drug: BI201335 24W
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI201335 for 24w
Study: NCT02435992
Drug: RPC1063
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02435992
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03879772
Drug: Placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasal administration
Study: NCT00183040
Drug: Topical testosterone
Normalized name: testosterone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01780506
Drug: E/C/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150/150/200/10 mg FDC tablet administered orally once daily
Study: NCT01780506
Drug: E/C/F/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150/150/200/300 mg FDC tablet administered orally once daily
Study: NCT01780506
Drug: E/C/F/TDF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once daily
Study: NCT01780506
Drug: E/C/F/TAF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once daily
Study: NCT04468139
Drug: Zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: zinc 50 mg orally daily dose will be taken orally by proven COVID-19 cases intervention
Study: NCT01851824
Drug: acenocoumarol
Normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg single oral doses on Days 1 and 23
Study: NCT03568136
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection in pre-filled syringe
Study: NCT02086240
Drug: XBD173
Approvals — FDA: no, EMA: no, PMDA: no
Description: XBD173 (Emapunil is an anxiolytic drug which acts as a selective agonist at the peripheral benzodiazepine receptor), a drug which binds the TSPO with high affinity.
Study: NCT00450814
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02484248
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo tablet looks identical to the ketotifen tablet, but does not contain ketotifen.
Study: NCT03450161
Drug: Fentanyl dosing schemes
Normalized name: fentanyl Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: We routinely use fentanyl as the opioid of choice in CABG surgery. However, how much and whether or not to apply it in boli or continuously remain uncertain. We will apply 3 routinely used fentanyl dosing schemes in our hospital. To blind care-givers and patients, in each of the arms a bolus and a continous injection will occur, as delineated in the treatment arms.
Study: NCT03777982
Drug: LHRH Agonist or Antagonist
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinizing hormone-releasing hormone (LHRH) agonists (also called LHRH analogs or GnRH agonists) are drugs that lower the amount of testosterone made by the testicles
Study: NCT00066274
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03969212
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPs less than 12 years old will receive placebo oral suspension and those above 12 years will receive placebo tablets. HHCs of IPs will not receive study medication.
Study: NCT00678782
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (NaCl) 0.5 ml intraarticular injection
Study: NCT03755934
Drug: MEDI7352
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive IV infusion of MEDI7352 as stated in arm description.
Study: NCT00066274
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00066274
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00066274
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03113773
Drug: Placebo Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose 5%
Study: NCT02103894
Drug: [18F]T807 ([18F]MNI-777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All enrolled subjects will undergo an \[18F\]MNI-777 PET imaging visit. For individuals with AD or CTE, \[18F\]florbetapir imaging may also be performed to serve as a means of correlating disease severity by evaluating the relationship of β-amyloid uptake (measured by \[18F\]florbetapir imaging) and tau protein uptake (measured by \[18F\]MNI-777 PET imaging). For individuals with Parkinsonian symptoms, \[123I\]β-CIT SPECT imaging may be performed to evaluate for a reduction in dopamine transporter uptake.
Study: NCT01069003
Drug: Placebo Arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and ASA (75 mg - 325 mg)
Study: NCT01069003
Drug: Thienopyridine Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 5 or 10 mg or Clopidogrel 75 mg plus ASA (75 mg - 325 mg)
Study: NCT04345120
Drug: SY-008 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY-008 matching placebo
Study: NCT00551642
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric Oxide vapour (gas) for inhalation (400 ppm)
Study: NCT00551642
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gas for inhalation
Study: NCT01992146
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no